EyePoint Pharmaceuticals, Inc. (EYPT)

EyePoint Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	71.14	99.7	281.26	95.63	178.59	44.91
Short-Term Investments	184.59	271.21	49.79	48.93	32.97	-
Cash & Short-Term Investments	255.73	370.91	331.05	144.56	211.56	44.91
Cash Growth	-8.75%	12.04%	129.00%	-31.67%	371.08%	102.16%
Receivables	0.63	0.61	0.81	15.5	18.35	9.45
Inventory	2.68	2.31	3.91	2.89	3.62	5.34
Prepaid Expenses	4.64	8.08	8.03	9.08	4.22	3.42
Other Current Assets	1.57	1.41	1.01	0.78	-	-
Total Current Assets	265.25	383.31	344.8	172.81	237.75	63.12
Property, Plant & Equipment	29.85	29.18	10.23	7.4	2.73	3.24
Other Intangible Assets	-	-	-	-	22.75	25.21
Other Long-Term Assets	6.05	5.98	0.15	0.15	0.15	0.15
Total Assets	301.15	418.47	355.18	180.36	263.37	91.72
Accounts Payable	19.69	11.72	6.5	5.92	7.39	4.81
Accrued Expenses	11.4	17.96	16.76	15.34	11.45	7.34
Short-Term Debt	-	-	-	10.48	-	-
Current Portion of Leases	1.9	1.25	0.56	0.54	0.78	0.69
Current Unearned Revenue	-	17.78	38.59	1.21	1.07	0.95
Other Current Liabilities	0.19	0.34	0.84	1.05	2.97	1.11
Total Current Liabilities	33.18	49.05	63.26	34.54	23.66	14.89
Long-Term Debt	-	-	-	29.31	36.56	37.98
Long-Term Leases	21.82	21.86	4.91	5.98	1.9	2.4
Long-Term Unearned Revenue	-	10.85	20.69	13.56	14.56	15.62
Other Long-Term Liabilities	0.15	0.21	-	0.6	2.32	2.29
Total Liabilities	55.14	81.96	88.86	83.99	78.99	73.18
Common Stock	0.07	0.07	0.05	0.03	0.03	0.02
Additional Paid-In Capital	1,223	1,208	1,008	766.9	752.6	528.36
Retained Earnings	-977.64	-873.02	-742.15	-671.35	-569.1	-510.68
Comprehensive Income & Other	0.83	1.03	0.86	0.79	0.84	0.84
Shareholders' Equity	246.01	336.5	266.32	96.37	184.38	18.54
Total Liabilities & Equity	301.15	418.47	355.18	180.36	263.37	91.72
Total Debt	23.72	23.11	5.47	46.31	39.24	41.07
Net Cash (Debt)	232.02	347.81	325.58	98.25	172.32	3.84
Net Cash Growth	-9.70%	6.83%	231.38%	-42.98%	4382.78%	-
Net Cash Per Share	3.59	6.18	8.37	2.63	5.99	0.30
Filing Date Shares Outstanding	68.93	68.73	49.83	34.3	34.04	28.74
Total Common Shares Outstanding	68.89	68.27	49.04	34.08	33.91	18.14
Working Capital	232.08	334.26	281.54	138.27	214.09	48.23
Book Value Per Share	3.57	4.93	5.43	2.83	5.44	1.02
Tangible Book Value	246.01	336.5	266.32	96.37	161.63	-6.67
Tangible Book Value Per Share	3.57	4.93	5.43	2.83	4.77	-0.37
Construction In Progress	-	1.51	3.73	-	-	-
Leasehold Improvements	-	4.13	1.01	1.01	0.26	0.26

Updated Aug 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q